Register Now for NAAF's 39th Annual Patient Conference June 27-30, 2024 in Washington, D.C.!

Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)

Study type: Clinical Trials Posting date: 05/22/2024 Last updated: 05/22/2024 Status: Recruiting Phase: Phase 2 Country: United States Eligibility:

Age at least 18 years ≤60 years for males or ≤70 years of age for females; diagnosis of  severe to very severe AA with ≥ 50% scalp hair loss; current episode of severe to very severe AA of less than 8 years

Drug: Rezpegaldesleukin link: Click here Location: Multiple locations


For more information, contact Necktar Recruitment at 855-482-8676 or by email at